Strong Customer Growth and Margin Improvement Justify Buy Rating for Redcare Pharmacy

Stifel Nicolaus analyst Yannik Siering maintained a Buy rating on Redcare Pharmacy (0RJT – Research Report) today and set a price target of €190.00.

Yannik Siering has given his Buy rating due to a combination of factors that highlight Redcare Pharmacy’s strong performance and growth potential. The company has demonstrated impressive customer growth, expanding its customer base significantly from the previous fiscal year. This increase in customers is a positive indicator of the company’s market presence and potential for future revenue growth.
Additionally, Redcare Pharmacy’s sales have shown substantial year-over-year growth, particularly in the German Rx segment, which experienced a remarkable increase. The company’s ability to improve its margins by reducing marketing intensity further supports the positive outlook. With these factors combined, Siering sees a promising future for Redcare Pharmacy, justifying the Buy rating.

In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a €170.00 price target.